Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 4/2022

Open Access 01-09-2022 | Migraine | Original Research

Circulating Insulin-Like Growth Factor 1 Levels and Migraine Risk: A Mendelian Randomization Study

Authors: Reziya Abuduxukuer, Peng-Peng Niu, Zhen-Ni Guo, Yu-Ming Xu, Yi Yang

Published in: Neurology and Therapy | Issue 4/2022

Login to get access

Abstract

Introduction

Preclinical studies have indicated insulin-like growth factor 1 (IGF1) as a novel therapeutic target in the treatment of migraines. We aimed to investigate the causal effect of circulating IGF1 levels on migraine risk using the two-sample Mendelian randomization method.

Methods

A total of 431 independent variants from 363,228 unrelated individuals in the UK Biobank were used as genetic instruments for circulating IGF1 levels. Summary-level data for migraines were obtained from two independent studies with 10,536 and 28,852 migraine cases, respectively.

Results

Mendelian randomization using inverse-variance weighting showed that increased IGF1 levels were significantly associated with decreased risk of migraines in both outcome datasets (odds ratio 0.905, 95% confidence interval 0.842–0.972, p = 0.006; odds ratio 0.929, 95% confidence interval 0.882–0.979, p = 0.006). Although some other robust Mendelian randomization methods did not demonstrate a significant association, no unbalanced horizontal pleiotropy was found by Mendelian randomization–Egger regression (p values for horizontal pleiotropy 0.232 and 0.435). The effect was confirmed in additional analyses including multivariable Mendelian randomization analyses.

Conclusion

This two-sample Mendelian randomization study showed that genetically determined increased IGF1 levels are causally associated with decreased migraine risk. Future randomized controlled trials are warranted to confirm the benefits of IGF1 administration on migraines.
Appendix
Available only for authorised users
Literature
1.
Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–18.PubMedCrossRef
2.
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15(1):80–101.PubMed
3.
4.
5.
Knuppel A, Fensom GK, Watts EL, et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK biobank. Can Res. 2020;80(18):4014–21.CrossRef
6.
Geng T, Wang M, Li X, et al. Birth weight modifies the relation between adulthood levels of insulin-like growth factor-1 and type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Res Care. 2021;9(1):000.CrossRef
7.
Carlzon D, Svensson J, Petzold M, et al. Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men. J Clin Endocrinol Metab. 2014;99(11):E2308–16.PubMedPubMedCentralCrossRef
8.
Aldhaleei WA, Bhagavathula AS, Alshehhi F. Dyke-Davidoff-Masson syndrome presenting as recurrent chronic headache in the late adult life. Brain Circ. 2020;6(2):123–5.PubMedPubMedCentralCrossRef
9.
Bibollet-Bahena O, Cui QL, Almazan G. The insulin-like growth factor-1 axis and its potential as a therapeutic target in central nervous system (CNS) disorders. Cent Nerv Syst Agents Med Chem. 2009;9(2):95–109.PubMedCrossRef
10.
Zappa Villar MF, Lopez Hanotte J, Crespo R, Pardo J, Reggiani PC. Insulin-like growth factor 1 gene transfer for sporadic Alzheimer’s disease: new evidence for trophic factor mediated hippocampal neuronal and synaptic recovery-based behavior improvement. Hippocampus. 2021;31(10):1137–53.PubMedCrossRef
11.
Chen SP, Ayata C. Novel therapeutic targets against spreading depression. Headache. 2017;57(9):1340–58.PubMedCrossRef
12.
Chen SP, Ayata C. Spreading depression in primary and secondary headache disorders. Curr Pain Headache Rep. 2016;20(7):44.PubMedCrossRef
13.
Smith GD, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.PubMedCrossRef
14.
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA. 2021;326(16):1614–21.PubMedCrossRef
15.
Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet. 2021;53(2):185–94.PubMedCrossRef
16.
Zhou Y, Qian X, Liu Z, et al. Coagulation factors and the incidence of COVID-19 severity: Mendelian randomization analyses and supporting evidence. Signal Transduct Target Ther. 2021;6(1):222.PubMedPubMedCentralCrossRef
17.
Cupido AJ, Kraaijenhof JM, Burgess S, Asselbergs FW, Hovingh GK, Gill D. Genetically predicted neutrophil-to-lymphocyte ratio and coronary artery disease: evidence from mendelian randomization. Circ Genom Precis Med. 2022;15(1): e003553.PubMedPubMedCentralCrossRef
18.
Taylor-Bateman V, Gill D, Georgakis M, Malik R, Munroe P, Traylor M. Cardiovascular risk factors and MRI markers of cerebral small vessel disease: a Mendelian randomization study. Neurology. 2021;98:343–51.CrossRef
19.
Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570–5.PubMedPubMedCentralCrossRef
20.
21.
Choquet H, Yin J, Jacobson AS, et al. New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis. Commun Biol. 2021;4(1):864.PubMedPubMedCentralCrossRef
22.
Banda Y, Kvale MN, Hoffmann TJ, et al. Characterizing race/ethnicity and genetic ancestry for 100,000 subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. Genetics. 2015;200(4):1285–95.PubMedPubMedCentralCrossRef
23.
Kvale MN, Hesselson S, Hoffmann TJ, et al. Genotyping informatics and quality control for 100,000 subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. Genetics. 2015;200(4):1051–60.PubMedPubMedCentralCrossRef
24.
Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3): e1001779.PubMedPubMedCentralCrossRef
25.
Minelli C, Del Greco MF, van der Plaat DA, Bowden J, Sheehan NA, Thompson J. The use of two-sample methods for Mendelian randomization analyses on single large datasets. Int J Epidemiol. 2021;50(5):1651–9.PubMedPubMedCentralCrossRef
26.
27.
28.
Zhang Z, Wang M, Yuan S, Cai H, Zhu S-G, Liu X. Genetically predicted coffee consumption and risk of Alzheimer’s disease and stroke. J Alzheimer’s Dis. 2021;83(4):1815–23.CrossRef
29.
Pistis G, Milaneschi Y, Vandeleur CL, et al. Obesity and atypical depression symptoms: findings from Mendelian randomization in two European cohorts. Transl Psychiatry. 2021;11(1):96.PubMedPubMedCentralCrossRef
30.
Howell AE, Robinson JW, Wootton RE, et al. Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study. BMC Cancer. 2020;20(1):508.PubMedPubMedCentralCrossRef
31.
32.
Yuan S, Daghlas I, Larsson SC. Alcohol, coffee consumption, and smoking in relation to migraine: a bidirectional Mendelian randomization study. Pain. 2022;163(2):e342–8.PubMedCrossRef
33.
Guo Y, Rist PM, Daghlas I, et al. A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine. Nature Commun. 2020;11(1):3368.CrossRef
34.
Daghlas I, Vgontzas A, Guo Y, Chasman DI, International Headache Genetics Consortium, Saxena R. Habitual sleep disturbances and migraine: a Mendelian randomization study. Ann Clin Transl Neurol. 2020;7(12):2370–80.PubMedPubMedCentralCrossRef
35.
Yin P, Anttila V, Siewert KM, Palotie A, Davey Smith G, Voight BF. Serum calcium and risk of migraine: a Mendelian randomization study. Hum Mol Genet. 2017;26(4):820–8.PubMed
36.
Hautakangas H, Winsvold BS, Ruotsalainen SE, et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nat Genet. 2022;54(2):152–60.PubMedPubMedCentralCrossRef
37.
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.PubMedPubMedCentralCrossRef
38.
39.
Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497–501.PubMedCrossRef
40.
Carro E, Trejo JL, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci. 2001;21(15):5678–84.PubMedPubMedCentralCrossRef
41.
Carlson SW, Saatman KE. Central infusion of insulin-like growth factor-1 increases hippocampal neurogenesis and improves neurobehavioral function after traumatic brain injury. J Neurotrauma. 2018;35(13):1467–80.PubMedPubMedCentralCrossRef
42.
Shandilya A, Mehan S. Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions. Neurol Sci. 2021;42(8):3145–66.PubMedCrossRef
43.
Grinberg YY, van Drongelen W, Kraig RP. Insulin-like growth factor-1 lowers spreading depression susceptibility and reduces oxidative stress. J Neurochem. 2012;122(1):221–9.PubMedPubMedCentralCrossRef
44.
Grinberg YY, Dibbern ME, Levasseur VA, Kraig RP. Insulin-like growth factor-1 abrogates microglial oxidative stress and TNF-alpha responses to spreading depression. J Neurochem. 2013;126(5):662–72.PubMedPubMedCentralCrossRef
45.
Malkov A, Ivanov AI, Popova I, et al. Reactive oxygen species initiate a metabolic collapse in hippocampal slices: potential trigger of cortical spreading depression. J Cereb Blood Flow Metab. 2014;34(9):1540–9.PubMedPubMedCentralCrossRef
46.
Shatillo A, Koroleva K, Giniatullina R, et al. Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system. Neuroscience. 2013;253:341–9.PubMedCrossRef
47.
48.
Won L, Kraig RP. Insulin-like growth factor-1 inhibits nitroglycerin-induced trigeminal activation of oxidative stress, calcitonin gene-related peptide and c-Fos expression. Neurosci Lett. 2021;751: 135809.PubMedPubMedCentralCrossRef
49.
Tepper SJ. Anti-calcitonin gene-related peptide (CGRP) therapies: update on a previous review after the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018;58(Suppl 3):276–90.PubMedCrossRef
50.
de Vries T, Villalon CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211: 107528.PubMedCrossRef
51.
Won L, Kraig RP. Insulin-like growth factor-1 inhibits spreading depression-induced trigeminal calcitonin gene related peptide, oxidative stress & neuronal activation in rat. Brain Res. 2020;1732: 146673.PubMedPubMedCentralCrossRef
52.
53.
Berryman DE, Glad CAM, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol. 2013;9(6):346–56.PubMedCrossRef
54.
Islam MR, Nyholt DR. Glucose-related traits and risk of migraine-a potential mechanism and treatment consideration. Genes (Basel). 2022;13(5):730.CrossRef
55.
56.
57.
Larsson SC, Carter P, Vithayathil M, Kar S, Mason AM, Burgess S. Insulin-like growth factor-1 and site-specific cancers: a Mendelian randomization study. Cancer Med. 2020;9(18):6836–42.PubMedPubMedCentralCrossRef
58.
Chen M, Tsai CW, Chang WS, et al. High circulating insulin-like growth factor-1 reduces the risk of renal cell carcinoma: a Mendelian randomization study. Carcinogenesis. 2021;42(6):826–30.PubMedCrossRef
59.
Tsai CW, Chang WS, Xu Y, Huang M, Bau DT, Gu J. Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk. Mol Carcinog. 2021;60(11):726–33.PubMedCrossRef
Metadata
Title
Circulating Insulin-Like Growth Factor 1 Levels and Migraine Risk: A Mendelian Randomization Study
Authors
Reziya Abuduxukuer
Peng-Peng Niu
Zhen-Ni Guo
Yu-Ming Xu
Yi Yang
Publication date
01-09-2022
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 4/2022
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-022-00398-w

Other articles of this Issue 4/2022

Neurology and Therapy 4/2022 Go to the issue

Commentary

Expert-Agreed Practical Recommendations on the Use of Cladribine

Original Research

Effectiveness of Training Programs for Reducing Adverse Psychological Outcomes in Parents of Children with Acquired Brain Injury: A Systematic Review and Meta-Analysis

Original Research

Neuroanatomy and Functional Connectivity in Patients with Parkinson’s Disease with or without Restless Legs Syndrome

Original Research

Verifynow P2Y12 PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study

Original Research

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

Review

Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review